FDA updates label for controversial Alzheimer’s drug aducanumab (Aduhelm)July 8, 2021Alzheimer's & CognitionNeurology
Heart failure med undertreatment because of older age common, flouts evidenceJuly 7, 2021Heart FailureCardiologyGeriatrics
What’s best for diabetes after metformin? GRADE outdated at outsetJuly 2, 2021DiabetesCAD & AtherosclerosisStrokePreventive CareHeart FailureHypertensionLipid Disorders
‘Stunning’ twincretin beats semaglutide for A1c, weight reduction in T2DJune 26, 2021DiabetesNephrologyLipid DisordersObesityCardiology
Promising HER2+/HR– breast cancer survival with de-escalated therapyJune 15, 2021Breast CancerASCO Breast CancerOncologyCancer
FDA: More metformin extended-release tablets recalledJune 14, 2021DiabetesPediatricsObesityEndocrinologyCardiology
Surgical outcomes favor addition of nivolumab to neoadjuvant chemo in resectable lung cancersJune 10, 2021Lung CancerASCO Lung CancerOncology
Schizophrenia meds a key contributor to cognitive impairmentJune 8, 2021Schizophrenia & Other Psychotic DisordersDepressionMajor Depressive DisorderMental HealthAnxiety DisordersSleep Medicine
Choosing the right R-CHOP dosage for elderly patients with DLBCLJune 8, 2021DLBCLB Cell LymphomaLymphoma & Plasma Cell DisordersOncologyHematologic MalignanciesGeriatrics
‘Remarkable’ response to diabetes drug in resistant bipolar depressionJune 7, 2021Bipolar DisorderDiabetesMajor Depressive DisorderMental HealthEndocrinology
FDA approves controversial Alzheimer’s drug aducanumab (Aduhelm)June 7, 2021Alzheimer's & CognitionNeurologyGeriatrics